Juvenescence develops therapeutics and technologies aimed at treating diseases of aging and extending healthy human longevity. The company combines world‑class scientists, seasoned drug developers, and machine‑learning experts to create a longevity ecosystem. It is pursuing a portfolio approach and aims to develop 12 therapeutic candidates within the field of healthy aging. Juvenescence creates, partners with, or invests in new companies, in‑licenses compounds from academia and industry, and forms joint ventures to advance longevity programs. Management says recent hires and expanded machine‑learning capabilities will help bring age‑modifying therapeutics to market. The company has raised significant capital to support these programs, positioning it to progress multiple programs to initial inflection points. Juvenescence develops therapeutics and partners or invests in companies focused on increasing healthy human longevity. Its core approach uses a partnership and licensing model to in‑license compounds, form joint ventures, and shepherd technologies toward clinical proof of concept and commercialisation. The company’s portfolio includes Insilico Medicine, Juvenescence AI (a joint venture with Insilico), NetraPharma, LyGenesis, and AgeX Therapeutics, and it has deals with the Buck Institute for Research on Aging. Juvenescence says it will advance some programs into the clinic in the medium term and commercialise others in the nearer term, and it plans to accelerate licensing and partnership arrangements. The company is increasing development of its AI‑generated programs and has key milestones targeted over the next 12 months. Juvenescence was formed in October 2016 and is led by a team including Jim Mellon, Dr Greg Bailey, Dr Declan Doogan and Dr Annalisa Jenkins. Juvenescence is a biotech company focused on developing therapeutics to increase healthy human longevity and treat diseases of ageing. Founded in 2017 and based in Tortola, British Virgin Islands, the company creates or invests in new companies, in-licenses compounds from academia or industry, and forms joint ventures to advance longevity therapeutics. After its founding, Juvenescence invested in Insilico Medicine and formed Juvenescence AI, which has a license to acquire five compound families per year from Insilico’s AI engine. The firm aims to assemble a portfolio of commercially viable therapeutic assets and take compounds into the clinic. Juvenescence recently closed an oversubscribed $12.3 million seed round with participation from institutional and angel investors, and two founders each invested $1.5 million. Proceeds will be used to establish collaborations with leading academic institutions around therapeutic candidates targeting ageing and age-related diseases.

Total raised

$162M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2019